Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nicotinamide Riboside in Peripheral Artery Disease
NCT07782671Phase 3Not yet recruiting
- Sponsor
- Northwestern University
- Start
- Dec 2026
- Primary completion
- Dec 2030
01
Overview
A Phase 3 trial of nicotinamide riboside in peripheral artery disease (PAD), sponsored by Northwestern University. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
nicotinamide riboside
03
Conditions
peripheral artery disease (PAD)
Beyond the preview
Go deeper on NCT07782671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07782671.